Cidara Thera CDTX

$221.38 +0.06 (0.03%)

Valuation

Market cap
6,948,960,000
Revenue TTM
$1,280,000
Net income TTM
$-169,830,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-13,267.97%
Debt to equity
0.00

Trading

Volume
2,691,000
Avg volume
1,496,326
Day's range
$221.25 – $221.41
Shares out
31,439,000
Stochastic %K
96%
Beta
1.52
Analysts
Moderate Buy
Price target
$207.30

Price

Company profile

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associat...

Show more

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 752 6170
Website
https://www.cidara.com
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Nov 18, 12:35 AM
$SLS all the short begging / sounds like pigs squealing before the slaughter. @Duncan74 lots of short shares Have to be Paid for. $CDTX was at $20 and Change when it announced its Phase 3 Results -- T1 trading Halt /like sls today // and it Jumped up to $50 and it Kept on Climbing - to over $100 per share like SLS WILL until it got bought for $220.... Like SLS will $CING $GLSI wishes they had heterocliticity Mark this Post.
1 replies
55X_ROI_Q1_2026 Nov 17, 10:16 PM
$SLS $MRNA $XBI Now the Offering is done - this will move Up Quickly and Bigly. Estimates at 300,000 AML Patients in United STATES Right Now CURRENTLY in REMISSION who'll immediately Benefit from GPS Right out of the GATE. 300,000 * $500K Revenue Per Patient $150B TAM Expect 65% Patient Uptake Rates SLS current $3.6B MCAP / $18 per share price is an illusion. $CDTX from $20 to $50 on the P3 News Kept Climbing to around $100 and then got bought for $220 ... This is going to what happens Here.
1 replies
55X_ROI_Q1_2026 Nov 17, 7:24 PM
$CDTX is an example of what will happen here at $SLS CDTX was trading in the low $20's - jumped to $50 on the P3 Announcement and KEPT CLIMBING to a $220 BUYOUT.... MARK THIS POST GPS is worth Every nickel of $40B to Big Pharma this $20 managed price $4B is a FLEETING GIFT //
2 replies
_nic Nov 17, 12:37 PM
$SLS $CDTX moment is here. @mattsprat
2 replies
SellasGPS24BAT14 Nov 12, 4:25 PM
$SLS $RVMD $ABVX $MRNA Sellas PPS will be halted multiple times in coming days. Volume will be over 200 Million shares on the day of GPS Regal Pivotal Registrational Breakthrough Phase 3 Data. SLS PPS will be halted multiple times that day and close over $120.00+ | have been part of $CDTX $RVMD • $ABVX run ups but SLS is in a league if it's own with CURATIVE data for one of the deadliest cancer on the planet. Market over corrects both ways, I don't think lot of people are mentally prepared about what coming here will be one of the most violent upticks in the History of Wall Street because GPS will be only CURATIVE cancer platforms with 0 Toxicity, 0 Adverse event, mild side effect of Injection site small bump, Excellent QOL. I am mentally prepared for an uptick from $120- $180 after multiple trading halts. ✌️🙏❤️‍🩹
0 replies
B2iDigital Nov 5, 3:24 PM
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: $LABT ) announced it has completed the redemption of all remaining outstanding shares of its Series C Convertible Preferred Stock. The Company redeemed 127,097 shares for an aggregate cash redemption price of $1,270,970, funded from cash on hand. Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1 Following the redemption: • No shares of Series C Preferred Stock remain outstanding • No additional shares of common stock will be issuable upon conversion of the Series C Preferred Stock • The Company has no shares of preferred stock outstanding and no outstanding indebtedness for borrowed money • All restrictions associated with the Series C Preferred Stock are eliminated Chief Executive Officer Kelvin Cooper, Ph.D., addressed the capital structure, financing restrictions and the development programs. "Completing this redemption simplifies our capital structure and eliminates the potential for further dilution from conversion of the Series C Preferred Stock," said Dr. Cooper. "It also removes the financing restrictions associated with that instrument, giving us greater financial flexibility as we continue to advance our development programs." Read the full release: https://lakewoodamedex.investorroom.com/2026-11-05-Lakewood-Amedex-Biotherapeutics-Announces-Completion-of-Series-C-Convertible-Preferred-Stock-Redemption Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted LABT stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $SPRO, $CDTX, $SCYX, $XBI
1 replies
B2iDigital Oct 29, 6:31 PM
Asked why infected diabetic foot ulcers so often progress beyond the mild stage, Charles Zelen, DPM, FACFAS, founder and president of PERI, the clinical research organization conducting the company's Phase 2a trial of Nu-3, told a Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: $LABT ) virtual roundtable that these patients are compromised hosts with multiple complex comorbidities and poor circulation. Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1 Zelen set out factors that, as he put it, have to be addressed simultaneously to heal these wounds: • Patients with poor circulation tend to have even greater problems dealing with infection and with bad wounds, he said • Neuropathy leaves patients unable to feel the infection going on, so it is often caught later, which he said makes it more difficult to treat • The wounds carry chronic inflammation and a complex wound environment, in his description, and antimicrobial resistance is also a big factor in this patient population Zelen closed by calling diabetic foot ulcers a serious and growing medical challenge, despite all the advances in wound care. "So this is a very big problem, very complicated problem, and one that we very much need to solve," Zelen noted, "or we're going to end up with a lot of lost extremities and a lot of deaths." Watch the full roundtable: https://youtu.be/EOIfDh8Vykk Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted LABT stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $SPRO, $CDTX, $SCYX, $XBI
1 replies
SellasGPS24BAT14 Oct 27, 11:01 PM
$SLS Incorrect! BlackRock Increasing Massively to 15,872,685 shares now, raising their stake before BO. Institutional whales will own 80% of the shares when the last 10k hits after BO. I saw the same with $CDTX and $TERN before they got BO! ✌️🙏❤️‍🩹
4 replies